J05AF11 - Telbivudine |
Propably not porphyrinogenic |
PNP |
Side effects
Common adverse reactions of telbividune that can be confused with an acute porphyric attack are diarrhoea, nausea and abdominal pains. These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Telbivudine is not metabolized by CYP450 enzymes and is not an inducer or mechanism-based inhibitor of CYP450 enzymes. No pharmacokinetic porphyrinogenic effects are suspected.
Chemical description
Synthetic thymidine nucleoside analogue
Therapeutic characteristics
Telbivudine is used in the treatment of chronic hepatitis B in adult patients with evidence of viral replication, and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. It is administered orally.
Metabolism and pharmakokinetics
Telmivudine is not a substrate, inhibitor or inducer of CYP450 enzymes (SPC). It is eliminated primarily by urinary secretion of unchanged drug (Lui 2008).
References
- Scientific articles
- Lui YY, Chan HL. A review of telbivudine for the management of chronic hepatitis B virus infection. Expert Opin Drug Metab Toxicol. 2008 Oct;4(10):1351-61. PMID 18798704. #1821
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Sebivo). #1822
Similar drugs
© NAPOS 2024